Compile Data Set for Download or QSAR
maximum 50k data
Found 719 Enz. Inhib. hit(s) with all data for entry = 2951
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386607((1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- ...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386608((2S,4R)-1-(2-(3- acetyl-5-(2- (pyridin-4- yloxy)py...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386609((5-(3-acetyl-1-(2- ((2S,4R)-2-((6- bromopyridin-2-...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386610((2S,4R)-1-(2-(3- acetyl-5-(2- (methylsulfonamido) ...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386611((1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- ...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386612((2S,4R)-1-(2-(3- acetyl-5-(2- aminopyrimidin- 5-yl...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386613((2S,4R)-1-(2-(3- acetyl-5-(2- aminopyrimidin- 5-yl...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386614((2S,4R)-1-(2-(3- acetyl-5-(2- aminopyrimidin- 5-yl...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386615((2S,4R)-1-(2-(3- acetyl-5-(2- methylpyrimidin- 5-y...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386616((2S,4R)-1-(2-(3- acetyl-5-(2- methylpyrimidin- 5-y...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386617((2S,4R)-1-(2-(3- acetyl-5-(2- aminopyrimidin- 5-yl...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386619((2S,4R)-1-(2-(3- acetyl-5-(2- ethylpyrimidin-5- yl...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386620((2S,4R)-1-(2-(3- acetyl-5-(2- isopropylpyrimidin- ...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386623((2S,4R)-1-(2-(3- acetyl-5-(2- methylpyrimidin- 5-y...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386626((1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- ...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386627((1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- ...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386628((2S,4R)-1-(2-(3- acetyl-5-(2- methylpyrimidin- 5-y...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386629((1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- ...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386630((1S,3S,5S)-2-(2- (3-acetyl-5-(2- methylpyrimidin- ...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386631((2S,4R)-1-(2-(3- acetyl-5-(2- aminopyrimidin- 5-yl...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386632((2S,4R)-1-(2-(3- acetyl-5-(2- methylpyrimidin- 5-y...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386633((2S,4R)-1-(2-(3- acetyl-5-(2- methylpyrimidin- 5-y...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386411((2S,4R)-1-(2-(3- acetyl-5-(2- methylpyrimidin- 5-y...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386635((2S,4R)-1-(2-(3- acetyl-5-(2- fluoropyrimidin- 5-y...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386636((2S,4R)-1-(2-(3- acetyl-5-(2- methylpyrimidin- 5-y...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386641((S)-1-(2-(3- acetyl-5- (quinolin-7-yl)- 1H-indazol...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386643((2S,4R)-1-(2-(3- acetyl-5-(2-((1,1- dioxidothietan...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386645((S)-1-(2-(3- acetyl-5-(2- methylpyrimidin- 5-yl)-1...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386647(US10287301, Compound 596 | US10822352, Comp No. 59...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386648((2S,4R)-1-(2-(5-(2- acetamidopyrimidin- 5-yl)-3-ac...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386649(5-(3-acetyl-1-(2- ((2S,4R)-2-((6- bromopyridin-2- ...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386650(5-(3-acetyl-1-(2- ((2S,4R)-2-((6- bromopyridin-2- ...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386651((2S,4R)-1-(2-(3- acetyl-5-(2- methylpyrimidin- 5-y...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386652((2S,4R)-1-(2-(3- acetyl-5-(2- methylpyrimidin- 5-y...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386653((2S,4R)-1-(2-(3- acetyl-5-(2- methylpyrimidin- 5-y...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386654((1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- ...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386655((2S,4R)-1-(2-(3- acetyl-5-(2- hydroxypyrimidin- 5-...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386656((1S,2S,5R)-3-(2- (3-acetyl-5-(2- methylpyrimidin- ...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386657((2S,4R)-1-(2-(3- acetyl-5-(2- methylpyrimidin- 5-y...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386658(US10287301, Compound 607 | US10822352, Comp No. 60...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386659((2S,4R)-1-(2-(3- acetyl-7-methyl- 5-(2- methylpyri...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386660((2S,4R)-1-(2-(3- acetyl-6-methyl- 5-(2- methylpyri...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386662((1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- ...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM386663((2S,4R)-1-(2-(3- acetyl-5-(2- methylpyrimidin- 5-y...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM351981(1-(2-((2S,4R)-2-(2'- chloro-2- fluorobiphenyl-3- y...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM351982(1-(2-((2S,4R)-2-(2'- chloro-2- fluorobiphenyl-3- y...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM351984(1-(2-((2S,4R)-2-(6- bromopyridin-2- ylcarbamoyl)-4...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM351985(1-(2-((1R,3S,5R)-3-(6- bromopyridin-2- ylcarbamoyl...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM351986(1-(2-((2S,4R)-2-(6- bromopyridin-2- ylcarbamoyl)-4...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM351987(1-(2-((1R,3S,5R)-3-(2'- chloro-2- fluorobiphenyl-3...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration was incubated with test compound at various conc...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 719 total ) | Next | Last >>
Jump to: